- Home
- OBIO vs ELDN Comparison
OBIO vs ELDN Comparison
Compare OBIO & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- ELDN
- Stock Information
- Founded
- OBIO 2017
- ELDN 2004
- Country
- OBIO United States
- ELDN United States
- Employees
- OBIO N/A
- ELDN N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- OBIO Health Care
- ELDN Health Care
- Exchange
- OBIO Nasdaq
- ELDN Nasdaq
- Market Cap
- OBIO 172.1M
- ELDN 164.1M
- IPO Year
- OBIO N/A
- ELDN N/A
- Fundamental
- Price
- OBIO $4.00
- ELDN $3.64
- Analyst Decision
- OBIO Strong Buy
- ELDN Strong Buy
- Analyst Count
- OBIO 4
- ELDN 2
- Target Price
- OBIO $14.00
- ELDN $12.50
- AVG Volume (30 Days)
- OBIO 351.1K
- ELDN 1.4M
- Earning Date
- OBIO 11-11-2025
- ELDN 11-11-2025
- Dividend Yield
- OBIO N/A
- ELDN N/A
- EPS Growth
- OBIO N/A
- ELDN N/A
- EPS
- OBIO N/A
- ELDN 0.21
- Revenue
- OBIO $2,944,000.00
- ELDN N/A
- Revenue This Year
- OBIO $29.26
- ELDN N/A
- Revenue Next Year
- OBIO $10.65
- ELDN N/A
- P/E Ratio
- OBIO N/A
- ELDN $16.41
- Revenue Growth
- OBIO 41.61
- ELDN N/A
- 52 Week Low
- OBIO $2.20
- ELDN $2.32
- 52 Week High
- OBIO $6.50
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- OBIO 67.99
- ELDN 69.68
- Support Level
- OBIO $3.53
- ELDN $3.18
- Resistance Level
- OBIO $4.04
- ELDN $3.76
- Average True Range (ATR)
- OBIO 0.33
- ELDN 0.27
- MACD
- OBIO 0.07
- ELDN 0.06
- Stochastic Oscillator
- OBIO 94.20
- ELDN 83.06
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.